Form 4: Jazz Pharma Officer Acquires Shares via Performance Vesting

Jazz Pharmaceuticals' SVP, Chief Accounting Officer, Patricia Carr, acquired 2,370 ordinary shares following the vesting of performance-based awards.

Summary

• Patricia Carr, SVP, Chief Accounting Officer of Jazz Pharmaceuticals plc, acquired 2,370 ordinary shares.
• The acquisition occurred on January 16, 2026, following the satisfaction and certification of performance-based vesting requirements for awards granted on March 3, 2023.
• The shares were acquired at a price of $0.0, indicating they were part of a compensation plan.
• Following this transaction, Patricia Carr directly beneficially owns 9,382 ordinary shares.

Sentiment

Score: 7

Explanation: The filing indicates an executive's performance targets were met, leading to an increase in their beneficial ownership, which is generally a positive sign for company performance and management alignment.

Positives

• Patricia Carr, SVP, Chief Accounting Officer, increased her direct beneficial ownership in Jazz Pharmaceuticals plc by 2,370 ordinary shares.
• The vesting of these shares indicates that performance-based requirements set for awards granted on March 3, 2023, were successfully met and certified.

Future Outlook

The filing does not contain specific forward-looking statements or guidance, but the successful vesting of performance awards suggests the company met certain internal performance targets.

Industry Context

This transaction is a routine insider filing, common across all industries, reflecting executive compensation structures tied to performance. It does not provide specific industry-related insights beyond the company's internal performance.

Stakeholder Impact

• Shareholders: Increased alignment between executive management and shareholder interests through direct equity ownership.
• Employees: May signal successful achievement of company-wide or departmental performance goals, potentially boosting morale.

Key Dates

Recommendation

This Form 4 reports a routine vesting of performance-based share awards for an executive, indicating the company met certain internal performance targets. While positive for management alignment, it does not provide new material information to warrant a change in investment recommendation. Investors should continue to hold based on broader company fundamentals and market conditions.

Keywords

Jazz Pharmaceuticals, JAZZ, Form 4, Insider Transaction, Stock Acquisition, Performance Shares, Executive Compensation, Patricia Carr, SVP Chief Accounting Officer